GLSI

Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical firm based in Stafford, Texas, focused on developing innovative immunotherapies for cancer treatment, particularly targeting HER2/neu-expressing tumors, such as breast cancer. The company's lead candidate, GP2, is designed to bolster the immune response against cancer cells, addressing critical unmet needs in oncology. With a robust pipeline of therapies and a commitment to advancing cancer care, Greenwich LifeSciences is strategically positioned to make meaningful contributions to patient outcomes in an evolving therapeutic landscape.